Plus   Neg

Citius Signs Option With Novellus To License Novel Stem-Cell Therapy For ARDS

Citius Pharmaceuticals Inc. (CTXR) said that it signed an exclusive six-month option agreement to in-license a stem-cell therapy for acute respiratory distress syndrome or ARDS from a subsidiary of Novellus Inc.

In Wednesday pre-market trade, CTXR is trading at $0.82, up $0.22 or 36.64 percent.

Novellus's patented process uses its exclusive non-immunogenic synthetic messenger ribonucleic acid or mRNA molecules to create induced pluripotent stem cells (iPSCs) that, in turn, generate mesenchymal stem cells or MSCs with superior immunomodulatory properties.

MSCs have been shown to be safe in over 900 clinical trials and to be safe and effective in treating a number of inflammatory diseases, including ARDS.

mesenchymal stem cells prevent and suppress cytokine storm believed to be the cause of the severe inflammation of ARDS and now seen in COVID-19 patients.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020. Walmart announced its decision to raise wages for around 165,000 hourly associates across all its U.S. stores starting October, and introduce a team-based operating model in Supercenters. In a tweet, the retail giant said, "Today we're introducing new leadership roles and cross-training opportunities, giving our associates more ways to grow their careers."
Follow RTT